M&A Deal Summary

Mallinckrodt Acquires Questcor Pharmaceuticals

On August 14, 2014, Mallinckrodt acquired life science company Questcor Pharmaceuticals for 5.8B USD

Acquisition Highlights
  • This is Mallinckrodt’s 2nd transaction in the Life Science sector.
  • This is Mallinckrodt’s largest (disclosed) transaction.
  • This is Mallinckrodt’s 4th transaction in the United States.
  • This is Mallinckrodt’s 2nd transaction in California.

M&A Deal Summary
Date 2014-08-14
Target Questcor Pharmaceuticals
Sector Life Science
Buyer(s) Mallinckrodt
Deal Type Add-on Acquisition
Deal Value 5.8B USD
Advisor(s) Centerview Partners (Financial)
Latham & Watkins
Matheson Keys & Kordzik (Legal)

Target

Questcor Pharmaceuticals

Anaheim, California, United States
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company that provides drugs for the treatment of autoimmune and inflammatory disorders.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Mallinckrodt

Dublin, United Kingdom
Category Company
Founded 1867
Sector Life Science
Employees2,673
Revenue 2.2B USD (2021)
DESCRIPTION

Mallinckrodt is a specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. Mallinckrodt was founded in 1867 and is based in Dublin, Ireland.

DEAL STATS #
Overall 4 of 12
Sector (Life Science) 2 of 9
Type (Add-on Acquisition) 4 of 10
State (California) 2 of 3
Country (United States) 4 of 11
Year (2014) 2 of 2
Size (of disclosed) 1 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-02-11 Cadence Pharmaceuticals

San Diego, California, United States

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.

Buy $1.3B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-04-16 Ikaria

Clinton, New Jersey, United States

Ikaria is a critical care therapeutics company. Ikaria is based in Clinton, New Jersey.

Buy $2.3B
Mergr

Product

Company

Legal